BioNTech SE (BNTX) Operating Income (2018 - 2026)

BioNTech SE has disclosed Operating Income across 9 years of filings, most recently posting -$1.1 billion for Q2 2026.

• In Q2 2026, Operating Income fell 94.29% year-over-year to -$1.1 billion; the TTM figure through Jun 2026 stood at -$2.3 billion (down 142.6% YoY), while the FY2025 annual figure was -$1.6 billion, down 16.44% from the prior year.
• Operating Income came in at -$1.1 billion for Q2 2026 at BioNTech SE, down from -$793.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $5.3 billion in Q1 2022 to a low of -$1.1 billion in Q2 2026.
• Average Operating Income over 5 years is $517.6 million, with a median of -$21.6 million recorded in 2024.
• Year-over-year, Operating Income jumped 166.04% in 2022 and slumped 575.48% in 2025.
• Over 5 years, Operating Income stood at $3.4 billion in 2022, then sank by 83.15% to $566.2 million in 2023, then plunged by 71.95% to $158.8 million in 2024, then sank by 336.63% to -$375.8 million in 2025, then slumped by 193.29% to -$1.1 billion in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$1.1 billion in Q2 2026, -$793.2 million in Q1 2026, and -$375.8 million in Q4 2025.